AOBiome Therapeutics is a therapeutics company, based in Newton, Massachusetts and founded in 2013, that developed strains of Ammonia Oxidizing Bacteria (AOB) to administer live in treatments that address inflammatory conditions.
January 5, 2017
On January 5, 2017 AOBiome completed their series C funding round with $30 million in funding from ICarbonX.
December 31, 2014
On December 31, 2014 AOBiome completed their series B funding round with $7.5 million in funding from Wakestream Ventures and Hedgewood.
August 28, 2014
On August 28, 2014 AOBiome completed their series A funding round with $576,500 in funding from undisclosed investors.
March 21, 2013
On March 21, 2013 AOBiome completed their seed funding round with $630,000 in funding from undisclosed investors.
On March 21, 2013 AOBiome completed their seed funding round with $630,000 in funding from undisclosed investors.
On August 28, 2014 AOBiome completed their series A funding round with $576,500 in funding from undisclosed investors.
On December 31, 2014 AOBiome completed their series B funding round with $7.5 million in funding from Wakestream Ventures and Hedgewood.
On January 5, 2017 AOBiome completed their series C funding round with $30 million in funding from ICarbonX.